Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Homologous Recombination Repair Deficiency (HRD) Testing in Newly Diagnosed Advanced-stage Epithelial Ovarian Cancer: Insights From the Italian Testing Landscape (HRD-Italy)

NCT07825181 is registered in ClinicalTrials.gov with Fondazione Policlinico Universitario Agostino Gemelli IRCCS as lead sponsor.

NCT NCT07825181
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07825181 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Homologous Recombination Repair Deficiency (HRD) Testing in Newly Diagnosed Advanced-stage Epithelial Ovarian Cancer: Insights From the Italian Testing Landscape (HRD-Italy)
Lead sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase
Observational
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
October 31, 2027
Enrollment
1,125 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

epithelial ovarian cancer